As of November 6, 2026, Abbott Laboratories has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on April 27, 2026 (Form 8-K, April 27, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Abbott Laboratories? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Abbott Laboratories reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-04-27. Every row below is cited to the filing it comes from, and this page adds each new change as Abbott Laboratories files it.
Also on the record for Abbott Laboratories
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| April 29, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 7.5% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| December 3, 2025 | Stake report, Schedule 13G/A, by The Vanguard Group | 10.05% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Abbott Laboratories now and the warning signs.
Free to see. No signup.
Keep reading
More on Abbott Laboratories and the records around it.
Companies that share a holder
- Vanguard Capital Management also filed stake reports on 1495 other companies: A10 Networks Inc (Oct 2026), Altisource Portfolio Solutions SA (Oct 2026), Alto Neuroscience Inc (Oct 2026)
- The Vanguard Group also filed stake reports on 2384 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Watch Abbott Laboratories
Get an email when Abbott Laboratories files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Abbott Laboratories?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Abbott Laboratories: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Abbott Laboratories covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
4 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-04-27 | Reported | not named in the filing | 8-K, 2026-04-27 |
New leaders reset buying decisions — get the Full Report on Abbott Laboratories: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Abbott Laboratories, with the record behind each one.
Find candidates like senior executive at Abbott LaboratoriesEvery change, in the filing's words
Reported
On April 24, 2026, Kevin Conroy was named to the Abbott Laboratories' ("Abbott") Board of Directors.
- On April 24, 2026, Abbott shareholders approved the adoption of the Abbott Laboratories 2026 Incentive Stock Program (the "2026 Program") at the Annual Meeting of Shareholders.
- The 2026 Program was adopted by Abbott's Board of Directors on February 20, 2026, subject to shareholder approval at the Annual Meeting.
- The 2026 Program replaces the Abbott Laboratories 2017 Incentive Stock Program, as amended and restated (the "2017 Program"), under which Abbott makes all of its equity-related incentive compensation awards.
- The 2026 Program, which is administered by the Compensation Committee of Abbott's Board of Directors, permits Abbott to grant nonqualified stock options, restricted stock awards, restricted stock units, performance awards, and other share-based awards (including stock appreciation rights, dividend equivalents and recognition awards) to non-employee directors and employees of Abbott and its subsidiaries.
- The 2026 Program has a term of ten years.
- For a more detailed description of the 2026 Program, see pages 79 through 86 of Abbott's Definitive Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission on March 13, 2026.
Tools for this story
Each opens in a new tab, filled in for Abbott Laboratories. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.